http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Ryu, Kwan-Woong,Jin, Jiyu,Park, Yong-Wan,Choi, Jeong-Hee The Korea Institute of Information and Commucation 2009 Journal of communications and networks Vol.11 No.1
Multicarrier direct sequence code division multiple access (MC DS-CDMA) is an attractive technique for achieving high data rate transmission. This is valid regardless of whether or not the potentially large peak-to-average power ratio (PAPR) is an important factor for its application. On the other hand, code select CDMA (CS-CDMA) is an attractive technique with constant amplitude transmission of multicode signal regardless of subchannels. This is achieved by introducing a code select method. In this paper, we propose a new multiple access scheme based on the combination of MC DS-CDMA and CS-CDMA. The proposed scheme, which we call MC CS-CDMA, includes as special cases the subclasses of MC DS-CDMA and CS-CDMA. This paper investigates the performance of these systems over a multipath frequency selective fading channel using a RAKE receiver with maximal ratio combiner. In addition, the PAPR of the proposed system is compared with that of both MC DS-CDMA and CS-CDMA. Simulation results demonstrate that the proposed system provides better PAPR reduction than MC DS-CDMA, at the expense of the complexity of the receiver and the number of available users. The numerical result demonstrates that the proposed system has better performance than MC DS-CDMA due to the increased processing gain and time diversity gain.
혈액투석중인 말기신부전 환자에서 Fludrocortisone acetate (FCA) 투여 후 혈청 칼륨 저하 효과
류봉관,강대웅,정지용,윤나라,신병철,박경희,정종훈,김현리 朝鮮大學校 附設 醫學硏究所 2005 The Medical Journal of Chosun University Vol.30 No.1
Background: Hyperkalemia is a commonly encountered problem in dialysis patients with end-stage renal disease. In this study we evaluated the effect of mineralocorticoid therapy (fludrocortisono acetate) on serum potassium level in the serum of hyperkalemic end-stage renal disease patients. Methods: Fourteen patients on hemodialysis receiving fludrocortisone acetate (FCA) 0.1 mg/day were observed for 2 months periods. Consecutive monthly biochemical profiles were compared for the druration of the pre-and post-treatment of FCA. Result: Fourteen patients with mean age (±SE) of 51.5 years (4 males and 10 females) and mean hemodialysis period of 51.9 months were studied. Mean serum potassium levels significantly fell (p<0.05) during the post-FCA period (5.2±0.66 mEq/L) compared with potassium levels during the pre-FCA (5.8±0.43 mEq/L) period. Pre-and post-FCA values were not different for sodium, chloride, protein, albumin, AST/ALT, glucose, blood nitrogen, creatinine, phosphate and calcium. Conclusions: FCA appears to decrease serum potassium value in patients with end-stage renal disease. These results suggested that FCA could be effective to treat hyperkalemia without any adverse effect in patients undergoing hemodialysis.
Koom, Woong Sub,Kim, Tae Hyun,Shin, Kyung Hwan,Pyo, Hong Ryull,Kim, Joo-Young,Kim, Dae Yong,Yoon, Myonggeun,Park, Sung Yong,Lee, Dae Ho,Ryu, Jun Sun,Jung, Yoo Seok,Lee, Sang Hyun,Cho, Kwan Ho Wiley Subscription Services, Inc., A Wiley Company 2008 Head & neck Vol.30 No.2
<B>Background.</B><P>Concurrent chemoradiotherapy is commonly used for locally advanced nasopharyngeal carcinoma (NPC). We retrospectively analyzed the clinical outcomes of simultaneous modulated accelerated radiotherapy (SMART) with concurrent chemotherapy.</P><B>Methods.</B><P>Between January 2003 and May 2005, 24 patients with stage IIB to IVB NPC underwent SMART encompassing 3 targets: gross tumor volume (GTV), high-risk subclinical disease (CTV1), and low-risk subclinical disease (CTV2). Daily fractions of 2.4, 2.15, and 1.9 Gy were delivered to GTV, CTV1, and CTV2 to a total dose of 64.8, 58.05, and 51.3 Gy in 27 fractions over 5.5 weeks, respectively. Fifteen patients received concurrent cisplatin (DDP group), and 9 received 5-fluorouracil plus cisplatin (FP group).</P><B>Results.</B><P>With a median follow-up of 26 months (range, 17–45 months), 3-year overall and local-, regional-, and distant-progression-free survivals were 96% and 93%, 87%, and 88%, respectively. Grade 3 acute mucositis and pharyngitis were observed in 16 (67%) and 14 (59%) patients, respectively. Severe acute mucositis (100% vs 47%) and pharyngitis (100% vs 34%) were more frequently observed in the FP group than the DDP group (p < .01).</P><B>Conclusions.</B><P>Despite short follow-up with a small number of patients, our preliminary results demonstrated encouraging local-regional control and survival at the cost of modest increase in treatment related toxicities. The total dose and fractionation scheme of SMART used in our study is feasible with no life-threatening or fatal complications. However, the administration of fluorouracil in addition to cisplatin during SMART was associated with increased acute and late toxicities, and it should be administered with caution. © 2007 Wiley Periodicals, Inc. Head Neck, 2008</P>